Amarjot Kaur | |
---|---|
Nationality | Indian |
Alma mater | Panjab University |
Occupation | Statistician |
Employer | Merck Research Laboratories |
Amarjot Kaur is an Indian statistician who in 2016 became the president of the International Indian Statistical Association. She works for Merck Research Laboratories, [1] as Executive Director of Clinical Biostatistics and Research Decision Sciences. [2] She is also the 2017 treasurer of the American Statistical Association, [3] and in 2013 she chaired the American Statistical Association Community of Applied Statisticians. [4]
Before joining Merck, Kaur earned her Ph.D. at Panjab University in Chandigarh, India, [5] where she also worked as a lecturer. [2] At Panjab, in the 1990s, Kaur published research in mathematical statistics on tests for stochastic dominance. [T2O] She joined Merck after postdoctoral research at Pennsylvania State University. [2] At Merck, she became the chief statistician on the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme, a large international study of treatments for arthritis. [CVO]
In 2014, she was elected to be a Fellow of the American Statistical Association. [6]
T2O. |
CVO. | Cannon, Christopher P; Curtis, Sean P; FitzGerald, Garret A; Krum, Henry; Kaur, Amarjot; Bolognese, James A; Reicin, Alise S; Bombardier, Claire; Weinblatt, Michael E; Van Der Heijde, Désirée; et al. (MEDAL programme steering committee) (2006), "Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison", The Lancet, 368 (9549): 1771–1781,
doi:
10.1016/S0140-6736(06)69666-9,
PMID
17113426,
S2CID
18464206
|
Amarjot Kaur | |
---|---|
Nationality | Indian |
Alma mater | Panjab University |
Occupation | Statistician |
Employer | Merck Research Laboratories |
Amarjot Kaur is an Indian statistician who in 2016 became the president of the International Indian Statistical Association. She works for Merck Research Laboratories, [1] as Executive Director of Clinical Biostatistics and Research Decision Sciences. [2] She is also the 2017 treasurer of the American Statistical Association, [3] and in 2013 she chaired the American Statistical Association Community of Applied Statisticians. [4]
Before joining Merck, Kaur earned her Ph.D. at Panjab University in Chandigarh, India, [5] where she also worked as a lecturer. [2] At Panjab, in the 1990s, Kaur published research in mathematical statistics on tests for stochastic dominance. [T2O] She joined Merck after postdoctoral research at Pennsylvania State University. [2] At Merck, she became the chief statistician on the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme, a large international study of treatments for arthritis. [CVO]
In 2014, she was elected to be a Fellow of the American Statistical Association. [6]
T2O. |
CVO. | Cannon, Christopher P; Curtis, Sean P; FitzGerald, Garret A; Krum, Henry; Kaur, Amarjot; Bolognese, James A; Reicin, Alise S; Bombardier, Claire; Weinblatt, Michael E; Van Der Heijde, Désirée; et al. (MEDAL programme steering committee) (2006), "Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison", The Lancet, 368 (9549): 1771–1781,
doi:
10.1016/S0140-6736(06)69666-9,
PMID
17113426,
S2CID
18464206
|